|
| |
Avant ImmunotherapeuticsAVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines against viral and bacterial diseases, including single-dose oral vaccines aimed a protecting travelers from cholera, typhoid fever and other illnesses. In addition, the company is conducting clinical studies of a proprietary vaccine candidate for cholesterol management. AVANT further leverages the value of its technology portfolio through corporate partnerships. Current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare, and vaccines addressed to human food safety and animal health.
| Contact Details: |
| 119 Fourth Avenue |
| Needham |
| |
| 02494 |
| United States of America |
| Tel: | 781 433 0771 |
| Fax: | 781 433 0262 |
| Email: | info@avantimmune.com |
| WWW: | www.avantimmune.com/
|
| |
Recent Publications by Avant Immunotherapeutics: |  |
Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice.
Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that... | 10th October, 2009
| AVANT Immunotherapeutics, Inc., Needham, Massachusetts 02494, USA.
| Hum Vaccin. 2009 Feb;5(2):79-84. Epub 2009 Mar 1.
|
Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
Enterotoxigenic Escherichia coli (ETEC) is the leading cause of traveler's... | 1st April, 2008
| AVANT Immunotherapeutics, Inc. 119 Fourth Avenue, Needham, MA 02494,
| Vaccine. 2007 Dec 12;25(51):8574-84. Epub 2007 Oct 26.
DOI Direct Link |
Vaccines for cholesterol management.
Over the last 50 years, several attempts have been made to harness the... | 28th September, 2007
| AVANT Immunotherapeutics Inc., 119 Fourth Ave., Needham, Massachusetts
| World J Surg. 2007 Apr;31(4):690-4.
DOI Direct Link |
Vaccines for the prevention of cardiovascular disease.
Atherosclerosis, especially coronary heart disease (CHD), remains a most... | 16th February, 2007
| AVANT Immunotherapeutics, Inc., 119 Fourth Avenue, Needham, MA 02494, USA.
| Vascul Pharmacol. 2006 Nov;45(5):253-7. Epub 2006 Aug 17.
DOI Direct Link |
Enterotoxigenic Escherichia coli virulence factors and vaccine approaches.
Enterotoxigenic Escherichia coli (ETEC) is recognized as one of the major... | 15th November, 2006
| AVANT Immunotherapeutics, Inc., St. Louis, MO, USA.
| Expert Rev Vaccines. 2004 Oct;3(5):585-95.
DOI Direct Link |
→View more Avant Immunotherapeutics research publications. |
Press Releases on Avant Immunotherapeutics:
|
 |
| New Report from PharmaPlus: HIV Pipelines & Deals |
1st December, 2003 |
Pharmaplus |
New Report from PharmaPlus: HIV Pipelines & Deals
At the end
of November 2003 the joint United Nations Program on HIV/AIDS and the World
Health Organization presented
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 506 times since April 2007, the link to the organisation's website has been followed 86 times Recent Search Terms used to find this page: avant immunothe | AVANT Immunotherapeutics | . Search for more companies in Needham Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Avant Immunotherapeutics |
